和邦生物(603077.SH):擬籌劃分拆子公司武駿光能上交所上市
格隆匯12月29日丨和邦生物(603077.SH)公佈,公司於2021年6月10日發佈《關於全資子公司增資擴股暨放棄增資權的公吿》(公吿編號:2021-34),承諾在此次增資完成後,公司控股子公司四川武駿光能股份有限公司(“武駿光能”)將實施股改,在滿足上市公司分拆上市的條件下,公司將實施、啟動分拆上市工作,並進行IPO申報。
目前武駿光能已經完成股改工作,為使武駿光能專業、專注於綠色能源領域,並在該領域取得更優、更強的發展,公司擬啟動武駿光能首次公開發行股票並上市的相關籌劃工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.